Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 3 mg) |
| Drug Class | Thrombopoietin receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Summary
- Lusutrombopag (Mulpleta) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- A total of 3 systematic reviews/meta-analyses were reviewed, providing insights into the efficacy and safety profile of lusutrombopag (Mulpleta).
- Clinical trials have shown that lusutrombopag effectively reduces the need for preoperative platelet transfusion in patients with chronic liver disease and severe thrombocytopenia.
- Compared to placebo, more patients treated with lusutrombopag achieved treatment response criteria such as increased platelet count during study period, thereby reducing their requirement for platelet transfusions or rescue therapy post-procedure.
- The risk of any bleeding event was significantly lower among those treated with lusutrombopag compared to placebo; however, rates of thrombotic events were similar between both groups indicating its relative safety profile.
- In comparison to other ThromboPoietin Receptor Agonists (TPO-RAs), avatromobap and lusutomab showed superior results in improving point estimates of platelet response when compared against placebos; specifically avatrobomap had non-significant advantage over Mulpleta but both drugs outperformed eltombropog, romiplostim and rituximab treatments according to one meta-analysis review.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Mulpleta (lusutrombopag) Prescribing Information. | 2020 | Shionogi Inc., Florham Park, NJ |